June 27, 2019 07:07 AM EDTUpdated July 3, 07:08 AM

Aclaris hammered as hair loss drug flops in PhII, days after FDA took issue with Eskata ads

Amber Tong

The topical treatment for alopecia areata that Aclaris Therapeutics licensed from Rigel Pharma has failed a mid-stage study for alopecia areata, leaving the company with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Aclaris hammered as hair loss drug flops in PhII, days after FDA took issue with Eskata ads

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Aclaris ham­mered as hair loss drug flops in PhII, days af­ter FDA took is­sue with Es­ka­ta ads

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Aclaris hammered as hair loss drug flops in PhII, days after FDA took issue with Eskata ads

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Soleno’s rare pediatric disease drug faces PDUFA delay by three months